Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose. The Food and Drug Administration issued a warning in May 2015 notifying that patients using this class of anti-diabetic drugs may develop DKA. Risk factors for DKA development among patients who take SGLT-2 inhibitors include carbohydrate intake/starvation or acute illness. In the current report, we aimed to present a case of euglycemic DKA using dapagliflozin treatment.
Primary Language | English |
---|---|
Subjects | Internal Diseases |
Journal Section | Case Reports |
Authors | |
Publication Date | March 7, 2021 |
Submission Date | February 8, 2021 |
Acceptance Date | March 6, 2021 |
Published in Issue | Year 2021 Volume: 3 Issue: Supplement 1 |